INCY
Incyte Corporation
INCY has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over INCY overall, supported by stronger fundamentals and stronger valuation.
INCY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Strong | |
| Strong |
INCY's revenue, cash flow and balance sheet are currently healthy, and its profitability is stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
INCY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 16x | $122 | — |
| Cheap | 17x | $31.41 | -74% |
| Fair | 30x | $56.29 | -54% |
| Expensive | 64x | $121 | -0.9% |
| Current | 65x | $122 | — |
Historical ranges are pointers, not guarantees.
INCY's PE is in its expensive range at 65x. If earnings grow as analysts expect, today's price would be 16x next year's earnings, in its cheap range.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over INCY in the historical PE scenario, which offers more potential upside but is not a forecast.
INCY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for INCY, with profitability improving. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
INCY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $7.78 | +314% |
| Q3 2026 | $1.88 | -68% |
| Q2 2026 | $7.85 | +83% |
| Q1 2026 | $7.08 | +3440% |
| Q4 2025 | $6.41 | +4173% |
| Q3 2025 | $5.85 | +4079% |
| Q2 2025 | $4.28 | +1089% |
| Q1 2025 | $0.20 | -94% |
| Q4 2024 | $0.15 | -94% |
INCY has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
INCY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.6B | +14% |
| Q2 2026 | $1.7B | +38% |
| Q1 2026 | $1.3B | +21% |
| Q4 2025 | $1.5B | +28% |
| Q3 2025 | $1.4B | +20% |
| Q2 2025 | $1.2B | +16% |
| Q1 2025 | $1.1B | +20% |
| Q4 2024 | $1.2B | +16% |
INCY's revenue has grown year over year every quarter since late 2020: $1.6B last quarter, up 14% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -45% | -78 points |
| Q2 2026 | 42% | -1.9 points |
| Q1 2026 | 24% | +4.2 points |
| Q4 2025 | 22% | -3.3 points |
| Q3 2025 | 32% | +20 points |
| Q2 2025 | 44% | +89 points |
| Q1 2025 | 19% | +9.1 points |
| Q4 2024 | 26% | +7.1 points |
INCY's operating margin was −45% last quarter, down 78 points from the same quarter a year ago, near the bottom of its range since 2019.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over INCY on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over INCY on profitability, with a higher operating margin.
INCY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2024 | $218.8M | +$324.4M |
| Q4 2023 | $147.7M | -44% |
| Q3 2023 | $147.8M | -45% |
| Q2 2023 | $306.5M | +89% |
| Q1 2023 | -$105.6M | -153% |
| Q4 2022 | $262.4M | +224% |
| Q3 2022 | $268.6M | +20% |
| Q2 2022 | $162.4M | +52% |
OSCR has the stronger cash trend. Its trailing FCF is up 545% versus its history, compared with INCY at up 68%.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
INCY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2.4% | -5M shares |
| 1 year | +0.9% | +1.8M shares |
| 3 years | -10% | -22.9M shares |
| 5 years | -8.5% | -19M shares |
| Available history | -7% | -15.3M shares |
INCY has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
| Q4 2024 | — |
| Q3 2024 | $103,000 |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
INCY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.5x | Net Cash |
| Q2 2026 | -2.1x | Net Cash |
| Q1 2026 | -2.0x | Net Cash |
| Q4 2025 | -1.9x | Net Cash |
| Q3 2025 | -1.6x | Net Cash |
| Q2 2025 | -1.5x | Net Cash |
| Q1 2025 | -7.4x | Net Cash |
| Q4 2024 | -11.2x | Net Cash |
INCY has the edge over OSCR on leverage, with a lower net debt burden relative to earnings.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
INCY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.3 | Neutral |
| Stochastic | 54.3 | Neutral |
INCY's weekly RSI is 58 (neutral) and its Stochastic is 54 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
INCY PE vs Healthcare Sector
| Metric | INCY | Sector median | Relative |
|---|---|---|---|
| PE | 65x | 26x | 150% above |
| PE % | 83 | 29 | 54 pts above |
INCY is trading at 65x earnings, a 150% premium to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over INCY on valuation relative to its sector.
INCY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $117.8 | 3.3% above |
| 20 week MA | $119.9 | 1.5% above |
| 50 week MA | $107.8 | 13% above |
| 100 week MA | $91.4 | 33% above |
| 200 week MA | $77.7 | 57% above |
INCY is in an uptrend: it's above all five of its weekly moving averages, and 57% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
INCY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $88.4 | $87.4 | -1.2% |
| 2021 | $87.4 | $73.5 | -16% |
| 2022 | $73.5 | $81.4 | +11% |
| 2023 | $81.4 | $62.8 | -23% |
| 2024 | $62.8 | $69.2 | +10% |
| 2025 | $69.2 | $100.1 | +45% |
| 2026 YTD | $100.1 | $121.7 | +22% |
INCY has finished lower in three of the last six years. It's up 22% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over INCY on returns for 2026, with the stronger performance.